Radium-223 is a new type of radiotherapy for men with advanced prostate cancer. It is expected to get a licence for use in the UK shortly.
The National Institute for Health and Clinical Excellence (NICE) is reviewing radium-223 to look at the costs, benefits and risks associated with using it. If NICE decides that radium-223 is cost-effective, they will provide guidance for healthcare professionals working in the NHS in England and Wales about how it should be used and who will be eligible to receive the drug.
NICE has asked Prostate Cancer UK to feed the views and experiences of people affected by prostate cancer into their review of radium-223.
We would like to hear your thoughts on this drug. Your opinions are very useful and will help us make sure that the views of people affected by prostate cancer are considered by NICE. We would still like to hear your views even if you have not heard of radium-223 before. More information on this drug and its uses can be found below.
This survey is completely anonymous. Prostate Cancer UK will use your answers to inform our response to NICE’s appraisal.
The deadline for responses to this is survey is Friday 17th May 2013.